Press release
Plexiform Neurofibroma Market share will expand till 2024
One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body.Request Sample Copy of the Report@
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14783
The most commonly observed tumor is cutaneous neurofibroma, plexiform neurofibroma market is characterized by the formation of small bumps under the skin, which proliferate in both size and number. Cutaneous neurofibromas though cause sensitivity and cosmetic issues, they cause negligible medical problems.
Another type of tumor that commonly affects NF1 patients is plexiform neurofibromas (pNFs) market. It is a benign tumor affecting peripheral nerves that follows the neural element proliferation. Around half of the NH1 affected patient population is usually prone to pNF. This type of tumor includes a range of cell types, such as mast cells, Schwann cells, macrophages, fibroblasts, neuronal axons, and perineural cells. It may also contain collagen and other similar extracellular matrix materials.
Plexiform neurofibrosis can occur anywhere in a body and tumors may continue to grow throughout the life span of a patient. If the neurofibroma converts into a malignant sarcoma or key organs of a body are compressed, it may also result in a deadly outcome. Among all the implictions of NF1, plexiform neurofibromas are the most exhaustive and widely observed. In addition to causing substantial morbidity, nPNF may result in disability, disfiguring, and functional impairment as well.
Rarely, plexiform neurofibromas may result in abnormal functioning of eyes, dysplasias, cognitive deficits, and cardiovascular disorders. Moreover, there are higher chances of acquiring gliomas, leukemias, neuroendocrine tumors, and sometimes breats cancer in females over 50 years of age.
As pNFs may affect any part of a human body, they generally lead to clinical complications. Those occurred in the areas near neck or head are especially complicated because they result in a range of functional deficits and facial feature disfiguring. Large tumor resections often come with a risk of functional destruction and neurological complications.
MRI and CT scans are used for primary diagnosis of pNFs. When it comes to selecting the right treatment option, medication is not considered the only option as it is proved to be inefficient in treating plexiform neurofibroma. Surgery is the only relatively effective therapy available today. Surgical excision starts with de-bulking, and does not assure cure. Tumors continue to regrow post-surgery and patients have to undergo multiple surgical interventions. Rapid tumor growth, tumor size and location, tumor’s microscopic extension, and neural involvement collectively make it difficult to implement a surgical procedure.
Combination chemotherapy is already being used against plexiform neurofibromas. Drugs, which are used in combination with chemotherapy serve to prevent the proliferation of tumors. Sometimes, tumors may also die. However, the efficacy of combination therapy is not considered a completely reliable option to treat pNF patients.
Other possible methods of treatment are being researched on but nothing substantial has been found yet, in terms of plexiform neurofibroma treatment. Being associated with neurofibromatosis type I, pNFs either reoccur or transform in a malignant stage. Moreover, the tumors are non-radioactive and thus chemotherapy also shows a limited impact. Evaluating clinical trials is quite challenging in case of plexiform neurofibromas, as they develop in an unpredictable manner, making it difficult to examine the objective response. Emergence of innovative techniques of neuroimaging might play a vital role in clinical trials and help to discover highly potential treatment options thereby.
Request TOC of the Report@
http://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=14783
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
Middle East and Africa (GCC, Southern Africa, North Africa)
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plexiform Neurofibroma Market share will expand till 2024 here
News-ID: 720760 • Views: …
More Releases from Transparency Market Research
Automotive Tinting Film Market to be Worth USD 7.5 Bn by 2035 - By Film Type / B …
The global automotive tinting film market was valued at US$ 4.8 billion in 2024 and is projected to reach US$ 7.5 billion by 2035, expanding at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2035. This steady growth reflects the increasing adoption of tinting films across passenger and commercial vehicles, supported by growing consumer awareness regarding comfort, safety, and vehicle preservation.
Preview crucial insights and findings from our…
Global Meat Substitutes Market Poised for Robust Growth, set to Reach 20,100.0 M …
The global meat substitutes market is undergoing a rapid transformation, emerging as one of the most dynamic and fast-evolving segments within the global food industry. According to the latest industry analysis, the market was valued at US$ 7,532.3 Mn in 2024 and is projected to reach US$ 20,100.0 Mn by 2035, expanding at a healthy compound annual growth rate (CAGR) of 9.4% from 2025 to 2035. This strong growth trajectory…
Wrist Dive Computer Market Outlook 2035: Global Market to Grow from US$ 258.6 Mn …
The global wrist dive computer market is steadily expanding as recreational and professional diving activities gain popularity worldwide. Valued at US$ 258.6 million in 2024, the market is projected to reach US$ 436.9 million by 2035, growing at a compound annual growth rate (CAGR) of 4.9% from 2025 to 2035. This growth reflects rising participation in scuba and freediving, increasing safety awareness among divers, and continuous innovation in wearable dive…
NOR Flash Market Outlook 2035: Automotive Electronics-Driven Growth to US$ 11.5 …
The global NOR Flash Market(https://www.transparencymarketresearch.com/nor-flash-market.html) was valued at US$ 2.6 Bn in 2024 and is projected to reach US$ 11.5 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2035. This sustained growth trajectory reflects the rising importance of reliable, fast-boot, and high-endurance non-volatile memory in embedded systems. Unlike data-centric storage technologies, NOR Flash remains indispensable for code storage, firmware execution, and mission-critical…
More Releases for NF1
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% duri …
Market Overview
The Neurofibromatosis Type 1 (NF1) market is undergoing a major transformation fueled by advancements in precision oncology, genetic diagnostics, and targeted therapies. NF1 is a common autosomal dominant disorder characterized by café-au-lait spots, plexiform neurofibromas, cutaneous neurofibromas, optic pathway gliomas, skeletal abnormalities, and increased tumor predisposition.
The global market for NF1-related therapies and associated tumor management was valued at an estimated USD 340-440 million in 2024. As novel targeted treatments…
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics).
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034" offers…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US.
Key NF1 Market Highlights
*
The Neurofibromatosis Type 1 treatment…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to R …
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often…
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
